<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485041</url>
  </required_header>
  <id_info>
    <org_study_id>SID123_DDI_I_2014</org_study_id>
    <nct_id>NCT02485041</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg</brief_title>
  <official_title>An Open Label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetic Interaction of Dapoxetine 30 mg and Mirodenafil 100 mg in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Chemicals Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Healthy male volunteers were administered alone and in combination with dapoxetine 30mg
      mirodenafil 100mg for three times, respectively and the pharmacokinetic interaction was
      compared between the two drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy male volunteers were randomized into one group among 6 sequential groups and were
      administered alone or in combination with dapoxetine 30mg mirodenafil 100mg in each period.
      Bloods were obtained at each time for pharmacokinetic analysis. Safety evaluation was also
      done during entire study period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose</time_frame>
    <description>Cmax of dapoxetine and mirodenafil</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose</time_frame>
    <description>AUC of dapoxetine and mirodenafil</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F</measure>
    <time_frame>predose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse events</measure>
    <time_frame>During 22 days from first administration of period 1</time_frame>
    <description>Incidence rate of Adverse events</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Drug Interaction Potentiation</condition>
  <arm_group>
    <arm_group_label>M→D→D+M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirodenafil(M) in period 1, Dapoxetine(D) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M→D+M→D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirodenafil(M) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Dapoxetine(D) in period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D→M→D+M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapoxetine(D) in period 1, Mirodenafil(M) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D→D+M→M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapoxetine(D) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Mirodenafil(M) in period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D+M→M→D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapoxetine+Mirodenafil(D+M) in period 1, Mirodenafil(M) in period 2, Dapoxetine(D) in period 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D+M→D→M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapoxetine+Mirodenafil(D+M) in period 1, Dapoxetine(D) in period 2, Mirodenafil(M) in period 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapoxetine 30mg</intervention_name>
    <description>Tablet, Orally administered</description>
    <arm_group_label>M→D→D+M</arm_group_label>
    <arm_group_label>M→D+M→D</arm_group_label>
    <arm_group_label>D→M→D+M</arm_group_label>
    <arm_group_label>D→D+M→M</arm_group_label>
    <arm_group_label>D+M→M→D</arm_group_label>
    <arm_group_label>D+M→D→M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirodenafil 100mg</intervention_name>
    <description>Table, Orally administered</description>
    <arm_group_label>M→D→D+M</arm_group_label>
    <arm_group_label>M→D+M→D</arm_group_label>
    <arm_group_label>D→M→D+M</arm_group_label>
    <arm_group_label>D→D+M→M</arm_group_label>
    <arm_group_label>D+M→M→D</arm_group_label>
    <arm_group_label>D+M→D→M</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male adults aged between 19 and 55

          -  Body mass index (BMI) in the range of 19 to 27 kg/m2

          -  Understand the requirements of the study and voluntarily consent to participate in the
             study

          -  Available for the entire study period

        Exclusion Criteria:

          -  Subject has a history such as liver diseases, kidneys, digestive system, respiratory
             system, endocrine system, nervous psychiatric, blood, cancer, cardiovascular diseases

          -  Subject with clinically significant vital signs (sitting position blood pressure) (90
             mmHg &gt; systolic blood pressure ≥ 140 mmHg, 60 mmHg &gt; diastolic blood pressure ≥ 90
             mmHg)

          -  History of drug abuse

          -  History of caffeine, alcohol, smoking abuse

               -  caffeine(coffee,tea,coke)&gt; 4cups/day

               -  smoking &gt; 10 cigarettes/day

               -  alcohol &gt; 140g/week

          -  Consumption of any grapefruit or grapefruit-containing juices over 1 cup a day

          -  Previously donate whole blood within 60 days or component blood within 30 days

          -  Subject has taken drugs which affects the ADME of investigational products

          -  Subject with known for hypersensitivity reactions to mirodenafil/ dapoxetine or other
             drugs

          -  Inadequate laboratory test result:

               -  AST(SGOT) or ALT(SGPT) or total bilirubin &gt; 1.5 x upper limit of normal range

          -  Subject considered as unsuitable based on medical judgement by investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-Gul Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2015</study_first_submitted>
  <study_first_submitted_qc>June 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>June 25, 2015</last_update_submitted>
  <last_update_submitted_qc>June 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dapoxetine</keyword>
  <keyword>Mirodenafil</keyword>
  <keyword>DDI study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirodenafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

